BR9811937A - Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados - Google Patents

Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados

Info

Publication number
BR9811937A
BR9811937A BR9811937-0A BR9811937A BR9811937A BR 9811937 A BR9811937 A BR 9811937A BR 9811937 A BR9811937 A BR 9811937A BR 9811937 A BR9811937 A BR 9811937A
Authority
BR
Brazil
Prior art keywords
bioavailability
increasing
fexofenadine
derivatives
patient
Prior art date
Application number
BR9811937-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Kin-Kai Hwang
Dennis H Giesing
Gail H Hurst
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of BR9811937A publication Critical patent/BR9811937A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A61K31/75—Polymers of hydrocarbons of ethene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BR9811937-0A 1997-08-14 1998-07-21 Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados BR9811937A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91156397A 1997-08-14 1997-08-14
PCT/US1998/015098 WO1999008690A1 (en) 1997-08-14 1998-07-21 Method of enhancing bioavailability of fexofenadine and its derivatives

Publications (1)

Publication Number Publication Date
BR9811937A true BR9811937A (pt) 2000-09-05

Family

ID=25430473

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811937-0A BR9811937A (pt) 1997-08-14 1998-07-21 Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados

Country Status (29)

Country Link
EP (1) EP1003528B1 (enExample)
JP (1) JP4295913B2 (enExample)
KR (1) KR100522985B1 (enExample)
CN (1) CN1143680C (enExample)
AR (1) AR018505A1 (enExample)
AT (1) ATE224721T1 (enExample)
AU (1) AU725965C (enExample)
BR (1) BR9811937A (enExample)
CA (1) CA2301267C (enExample)
CZ (1) CZ293666B6 (enExample)
DE (1) DE69808303T2 (enExample)
DK (1) DK1003528T3 (enExample)
EE (1) EE04263B1 (enExample)
ES (1) ES2179523T3 (enExample)
HU (1) HU226823B1 (enExample)
ID (1) ID24463A (enExample)
IL (1) IL134521A (enExample)
NO (1) NO325148B1 (enExample)
NZ (1) NZ502133A (enExample)
OA (1) OA11287A (enExample)
PL (1) PL191607B1 (enExample)
PT (1) PT1003528E (enExample)
RU (1) RU2197967C2 (enExample)
SK (1) SK283868B6 (enExample)
TR (1) TR200000419T2 (enExample)
TW (1) TWI240633B (enExample)
UA (1) UA64765C2 (enExample)
WO (1) WO1999008690A1 (enExample)
ZA (1) ZA987221B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69624559T2 (de) 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
EP0998272B1 (en) * 1997-08-26 2003-05-02 Aventis Pharmaceuticals Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
WO2003101437A2 (en) * 2002-05-29 2003-12-11 Aventis Pharmaceuticals Holdings Inc. Method of treating asthma using fexofenadine
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
JP2008120684A (ja) * 2005-03-07 2008-05-29 Kumamoto Univ 抗アレルギー薬
KR101106374B1 (ko) 2009-06-05 2012-01-19 민병욱 고체연료에 의한 가연성 가스 발생 장치
KR101117014B1 (ko) * 2009-09-09 2012-06-14 민병욱 부패성 폐기물의 바이오매스 처리에 의한 폐자원 재활용 방법 및 장치
CN101843616B (zh) * 2010-06-04 2011-07-27 西安万隆制药有限责任公司 一种盐酸非索非那定与微晶纤维素组合物及其制备方法
RU2453315C2 (ru) * 2010-08-17 2012-06-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения аллергических заболеваний
EA201391742A1 (ru) 2011-05-20 2014-04-30 Авентис Фармасьютикалз Инк. Фармацевтическая композиция, включающая фексофенадин
RU2504018C1 (ru) * 2012-05-28 2014-01-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения и социального развития Российской Федерации Способ моделирования состояния индукции функциональной активности гликопротеина-р финастеридом в эксперименте
RU2553362C1 (ru) * 2014-01-09 2015-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ моделирования состояния ингибирования функциональной активности гликопротеина-р линестренолом в эксперименте
CN104188998A (zh) * 2014-09-18 2014-12-10 中山大学 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
NO900427L (no) * 1989-01-31 1990-08-01 Int Pharma Agentur Erosjonsregulert frigjoeringssystem for aktive stoffer og en fremgangsmaate for deres fremstilling.
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
AU5893796A (en) * 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides

Also Published As

Publication number Publication date
NO20000706L (no) 2000-04-13
CZ293666B6 (cs) 2004-06-16
EP1003528A1 (en) 2000-05-31
RU2197967C2 (ru) 2003-02-10
ZA987221B (en) 1999-02-15
DE69808303D1 (de) 2002-10-31
SK1842000A3 (en) 2000-08-14
HU226823B1 (hu) 2009-11-30
NZ502133A (en) 2002-03-28
IL134521A0 (en) 2001-04-30
UA64765C2 (uk) 2004-03-15
WO1999008690A1 (en) 1999-02-25
DK1003528T3 (da) 2003-02-03
PL191607B1 (pl) 2006-06-30
CN1267221A (zh) 2000-09-20
HK1025901A1 (en) 2000-12-01
EE200000069A (et) 2000-10-16
CA2301267A1 (en) 1999-02-25
PL338579A1 (en) 2000-11-06
JP4295913B2 (ja) 2009-07-15
ATE224721T1 (de) 2002-10-15
KR100522985B1 (ko) 2005-10-21
CN1143680C (zh) 2004-03-31
SK283868B6 (sk) 2004-03-02
CZ2000522A3 (cs) 2000-09-13
DE69808303T2 (de) 2003-05-22
ID24463A (id) 2000-07-20
EP1003528B1 (en) 2002-09-25
AU725965B2 (en) 2000-10-26
OA11287A (en) 2003-10-22
NO20000706D0 (no) 2000-02-11
AU8505098A (en) 1999-03-08
AU725965C (en) 2004-04-22
TR200000419T2 (tr) 2000-09-21
HUP0003189A2 (en) 2001-03-28
EE04263B1 (et) 2004-04-15
KR20010022845A (ko) 2001-03-26
AR018505A1 (es) 2001-11-28
PT1003528E (pt) 2003-02-28
HUP0003189A3 (en) 2001-04-28
JP2001515041A (ja) 2001-09-18
CA2301267C (en) 2004-07-13
NO325148B1 (no) 2008-02-11
TWI240633B (en) 2005-10-01
ES2179523T3 (es) 2003-01-16
IL134521A (en) 2005-07-25

Similar Documents

Publication Publication Date Title
WO2001005392A3 (en) Method for treating chronic pain using mek inhibitors
BR9811099A (pt) Inibidores de urocinase
WO2001005390A3 (en) Method for treating chronic pain using mek inhibitors
FI970825A7 (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyö tyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
BR9813228A (pt) Formulação de 2-metil-tieno-benzodiazepina
EE9900441A (et) Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nende solvaatide suu kaudu manustamiseks
ATE293970T1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
EE200000522A (et) Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
BR9914044A (pt) ésteres tetrahidropirido
AU2001249329A1 (en) Lipoxin analogs and methods for the treatment of periodontal disease
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
NO952890D0 (no) Kombinasjonsbehandling for inhibisjon av bentap
SG44989A1 (en) Crystalline hydrochloride of (R)-(-)-2-{N-[4-(1,1-dioxid-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman
DK0998287T3 (da) Anvendelse af levobupivacain
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
CA2301267A1 (en) Method of enhancing bioavailability of fexofenadine and its derivatives
WO1999012570A3 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DK1119359T3 (da) 2-methyl-thieno-benzodiazepinformulering
FR2688118B1 (fr) Nouvelles compositions fongicides a base d'inhibiteurs de la biosynthese des sterols.
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
EP0744176A3 (en) Methods for inhibiting bone loss
CO5580773A2 (es) Rosuvastatina en estados pre dementes
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
CA2119777A1 (en) An Ameliorant for Blood Lipid Metabolism

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AOS ARTS. 8O, 13, 24 E 25 DA LPI.

B25D Requested change of name of applicant approved

Owner name: AVENTIS PHARMACEUTICALS INC. (US)

Free format text: ALTERADO DE: HOECHST MARION ROUSSEL, INC.

B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070033918/RJ DE 19/03/2007.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDAS AS ALT. DE NOME E SEDE REQUERIDAS ATRAVES DA PETICAO NO 020080090002/RJ DE 27/06/2008, POR AUSENCIA DE FUNDAMENTACAO LEGAL, UMA VEZ QUE O PEDIDO FOI ARQUIVADO DEFINITIVAMENTE NA RPI 2060 DE 29/06/2010.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO DE TRANSFERENCIA NO 020100076561/RJ DE 18/08/2010, POR AUSENCIA DE FUNDAMENTACAO LEGAL, EM VIRTUDE DO ARQUIVAMENTO DEFINITIVO DO PEDIDO PUBLICADO NA RPI 2060 DE 29/06/2010.

B25B Requested transfer of rights rejected

Owner name: AVENTIS PHARMACEUTICALS INC. (US)

B25B Requested transfer of rights rejected

Owner name: AVENTIS PHARMACEUTICALS INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]